- 中国精品科技期刊
- 中国高校百佳科技期刊
- 中国中文核心期刊
- 中国科学引文数据库核心期刊
| Citation: |
QIAN Qianqian, LI Guozhi, TIAN Hong, et al. Design, preparation, and antitumor activity of fusion protein vaccine based on tumor antigen PBK[J]. J China Pharm Univ, 2024, 55(5): 657 − 665. DOI: 10.11665/j.issn.1000-5048.2024030801
|
PBK is a cancer/testis antigen that exhibits absent expression in various normal human tissues, but undergoes aberrant overexpression upon cellular transformation, thereby promoting the initiation, metastasis and even drug resistance of cancer. Consequently, it represents a novel target for tumor immunotherapy. In this study, PBK-Nitrath, a protein vaccine specifically designed to target PBK by fusing nitrated T epitope with the PBK protein was developed, using the IFN-γ ELISpot method to evaluate the activation level of PBK antigen-specific T cells in the spleen of immunized mice, and conducting in vitro cytotoxicity T cell killing efficacy test to evaluate the killing ability against H22 hepatic carcinoma cells; the anti-tumor activity was evaluated using a H22 hepatic carcinoma subcutaneous transplantation tumor model, and the differentiation of peripheral blood and spleen T lymphocytes and tumor immune infiltration were analyzed by flow cytometry. Results showed that PBK-Nitrath could efficiently induce the activation of antigen-specific T cells against PBK while enhancing cytotoxic T lymphocyte-mediated killing capacity, significantly impede hepatic carcinoma progression in mice and increase the ratio of CD8+CD107a+ T cells within peripheral blood and spleen, and facilitate tumor lymphocyte infiltration. Our findings reveal the potential utility of PBK-Nitrath as an effective candidate for tumor vaccine.
| [1] |
Park JH, Lin ML, Nishidate T, et al. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer[J]. Cancer Res, 2006, 66(18): 9186-9195. doi: 10.1158/0008-5472.CAN-06-1601
|
| [2] |
Huang H, Lee MH, Liu KD, et al. PBK/TOPK: an effective drug target with diverse therapeutic potential[J]. Cancers, 2021, 13(9): 2232. doi: 10.3390/cancers13092232
|
| [3] |
Park JH, Nishidate T, Nakamura Y, et al. Critical roles of T-LAK cell-originated protein kinase in cytokinesis[J]. Cancer Sci, 2010, 101(2): 403-411. doi: 10.1111/j.1349-7006.2009.01400.x
|
| [4] |
Zhang Y, Yang XJ, Wang R, et al. Prognostic value of PDZ-binding kinase/T-LAK cell-originated protein kinase (PBK/TOPK) in patients with cancer[J]. J Cancer, 2019, 10(1): 131-137. doi: 10.7150/jca.28216
|
| [5] |
Herbert KJ, Ashton TM, Prevo R, et al. T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics[J]. Cell Death Dis, 2018, 9(11): 1089. doi: 10.1038/s41419-018-1131-7
|
| [6] |
Han ZP, Li LZ, Huang YY, et al. PBK/TOPK: a therapeutic target worthy of attention[J]. Cells, 2021, 10(2): 371. doi: 10.3390/cells10020371
|
| [7] |
Kim DJ, Li Y, Reddy K, et al. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth[J]. Cancer Res, 2012, 72(12): 3060-3068. doi: 10.1158/0008-5472.CAN-11-3851
|
| [8] |
Matsuo Y, Park JH, Miyamoto T, et al. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis[J]. Sci Transl Med, 2014, 6(259): 259ra145.
|
| [9] |
Hu ZT, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer[J]. Nat Rev Immunol, 2018, 18(3): 168-182. doi: 10.1038/nri.2017.131
|
| [10] |
Wong KK, Li WA, Mooney DJ, et al. Advances in therapeutic cancer vaccines[J]. Adv Immunol, 2016, 130: 191-249.
|
| [11] |
Pedersen SR, Sørensen MR, Buus S, et al. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy[J]. J Immunol, 2013, 191(7): 3955-3967. doi: 10.4049/jimmunol.1300555
|
| [12] |
Yang YQ, Teng QX, Wu ZX, et al. PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study[J]. Mol Cancer, 2022, 21(1): 40. doi: 10.1186/s12943-022-01512-0
|
| [13] |
Duan ZH, Yang DD, Yuan P, et al. Advances, opportunities and challenges in developing therapeutic cancer vaccines[J]. Crit Rev Oncol Hematol, 2024, 193: 104198. doi: 10.1016/j.critrevonc.2023.104198
|
| [14] |
Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy[J]. Nat Rev Cancer, 2020, 20(11): 662-680. doi: 10.1038/s41568-020-0285-7
|
| [15] |
Wang JC, Sun X, Ma Q, et al. Metformin’s antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization[J]. J Cell Mol Med, 2018, 22(8): 3825-3836. doi: 10.1111/jcmm.13655
|
| [16] |
Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy[J]. Cell, 2017, 168(4): 707-723. doi: 10.1016/j.cell.2017.01.017
|
| [17] |
Borst J, Ahrends T, Bąbała N, et al. CD4+ T cell help in cancer immunology and immunotherapy[J]. Nat Rev Immunol, 2018, 18(10): 635-647. doi: 10.1038/s41577-018-0044-0
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Total visits：292824
DownLoad: